• Shopping Cart
    There are no items in your cart

ASTM F 1439 : 2024

Current

Current

The latest, up-to-date edition.

Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials

Available format(s)

Hardcopy , PDF

Language(s)

English

Published date

01-12-2024

€56.53
Excluding VAT

Committee
F 04
DocumentType
Guide
Pages
6
PublisherName
American Society for Testing and Materials
Status
Current
Supersedes

1.1This guide is intended to assist the testing laboratory in the conduct and evaluation of tumorigenicity tests to evaluate the potential for materials to evoke a neoplastic response.

1.2Carcinogenicity, which includes tumorigenic potential, is one of several biological effects that should be considered when evaluating the biological response to a material or a final, finished medical device as recommended in Practice F748. It is assumed that the evaluator has already determined that this type of testing is necessary for a particular material or medical device before consulting this guide. The recommendations of Practice F748 should be considered before a study is commenced.

1.3Whenever possible, it is recommended that a battery of genotoxicity tests be proposed and initiated as an alternative to an in vivo tumorigenicity bioassay. Chemical information and data from the literature regarding non-genotoxic carcinogens, if present, may also be considered when evaluating the carcinogenic potential. Genotoxicity assays may also be considered as initial screening procedures due to the sensitivity of the assays, the significant reduction in time to gain valuable data, and the desire to reduce the use of animals for testing. Genotoxicity assays that may be considered are outlined in Guide E1262 and in OECD 471, OECD 487, and OECD 490. The investigator is advised to carefully consider the appropriateness of a particular method for application after a review of the published literature.

1.4This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.5This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

ASTM F 2064 : 2017 Standard Guide for Characterization and Testing of Alginates as Starting Materials Intended for Use in Biomedical and Tissue Engineered Medical Product Applications
ASTM F 748 : 2016 Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices
ASTM E 3219 : 2020 Standard Guide for Derivation of Health-Based Exposure Limits (HBELs)
ASTM F 2212 : 2020 Standard Guide for Characterization of Type I Collagen as Starting Material for Surgical Implants and Substrates for Tissue Engineered Medical Products (TEMPs)
ASTM F 2347 : 2024 Standard Guide for Characterization and Testing of Hyaluronan as Starting Materials Intended for Use in Biomedical and Tissue Engineered Medical Product Applications
ASTM F 3089 : 2023 Standard Guide for Characterization and Standardization of Polymerizable Collagen-Based Products and Associated Collagen-Cell Interactions
ASTM F 2103 : 2018 Standard Guide for Characterization and Testing of Chitosan Salts as Starting Materials Intended for Use in Biomedical and Tissue-Engineered Medical Product Applications

Access your standards online with a subscription

Features

  • Simple online access to standards, technical information and regulations.

  • Critical updates of standards and customisable alerts and notifications.

  • Multi-user online standards collection: secure, flexible and cost effective.